RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $41
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $38 to $41.
RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $38 to $41.